Literature DB >> 25982269

Monoclonal antibodies to HLA-E bind epitopes carried by unfolded β2 m-free heavy chains.

Elisa Tremante1, Elisa Lo Monaco1, Tiziano Ingegnere1, Camilla Sampaoli1, Rocco Fraioli1, Patrizio Giacomini1.   

Abstract

Since HLA-E heavy chains accumulate free of their light β2 -microglobulin (β2 m) subunit, raising mAbs to folded HLA-E heterodimers has been difficult, and mAb characterization has been controversial. Herein, mAb W6/32 and 5 HLA-E-restricted mAbs (MEM-E/02, MEM-E/07, MEM-E/08, DT9, and 3D12) were tested on denatured, acid-treated, and natively folded (both β2 m-associated and β2 m-free) HLA-E molecules. Four distinct conformations were detected, including unusual, partially folded (and yet β2 m-free) heavy chains reactive with mAb DT9. In contrast with previous studies, epitope mapping and substitution scan on thousands of overlapping peptides printed on microchips revealed that mAbs MEM-E/02, MEM-E/07, and MEM-E/08 bind three distinct α1 and α2 domain epitopes. All three epitopes are linear since they span just 4-6 residues and are "hidden" in folded HLA-E heterodimers. They contain at least one HLA-E-specific residue that cannot be replaced by single substitutions with polymorphic HLA-A, HLA-B, HLA-C, HLA-F, and HLA-G residues. Finally, also the MEM-E/02 and 3D12 epitopes are spatially distinct. In summary, HLA-E-specific residues are dominantly immunogenic, but only when heavy chains are locally unfolded. Consequently, the available mAbs fail to selectively bind conformed HLA-E heterodimers, and HLA-E expression may have been inaccurately assessed in some previous oncology, reproductive immunology, virology, and transplantation studies.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  -B; -C; Conformation; HLA-A; HLA-E; mAbs; β2-microglobulin (β2m)

Mesh:

Substances:

Year:  2015        PMID: 25982269     DOI: 10.1002/eji.201545446

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling.

Authors:  Hannah Wurzer; Liza Filali; Céline Hoffmann; Max Krecke; Andrea Michela Biolato; Jérôme Mastio; Sigrid De Wilde; Jean Hugues François; Anne Largeot; Guy Berchem; Jérôme Paggetti; Etienne Moussay; Clément Thomas
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

2.  HLA-E expression and its clinical relevance in human renal cell carcinoma.

Authors:  Barbara Seliger; Simon Jasinski-Bergner; Dagmar Quandt; Christine Stoehr; Juergen Bukur; Sven Wach; Wolfgang Legal; Helge Taubert; Bernd Wullich; Arndt Hartmann
Journal:  Oncotarget       Date:  2016-10-11

3.  ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function.

Authors:  Silvia D'Amico; Valerio D'Alicandro; Mirco Compagnone; Patrizia Tempora; Giusy Guida; Paolo Romania; Valeria Lucarini; Ombretta Melaiu; Michela Falco; Mattia Algeri; Daniela Pende; Loredana Cifaldi; Doriana Fruci
Journal:  Front Immunol       Date:  2021-11-30       Impact factor: 7.561

4.  Stability and Expression Levels of HLA-C on the Cell Membrane Modulate HIV-1 Infectivity.

Authors:  Francesca Parolini; Priscilla Biswas; Michela Serena; Francesca Sironi; Valentina Muraro; Elisabetta Guizzardi; Lucia Cazzoletti; Maria Teresa Scupoli; Davide Gibellini; Elisabetta Ugolotti; Roberto Biassoni; Alberto Beretta; Mauro Malnati; Maria Grazia Romanelli; Donato Zipeto
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

Review 5.  The Potential of Soluble Human Leukocyte Antigen Molecules for Early Cancer Detection and Therapeutic Vaccine Design.

Authors:  Amy L Kessler; Marco J Bruno; Sonja I Buschow
Journal:  Vaccines (Basel)       Date:  2020-12-18

Review 6.  Deregulation of HLA-I in cancer and its central importance for immunotherapy.

Authors:  Ahmet Hazini; Kerry Fisher; Len Seymour
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.